Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

Search

Medicines Law & Policy Research and resources on intellectual property and health

Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

Tag: UNITAID

Updated TRIPS Flexibilities Database

Ellen 't Hoen - April 17, 2023

The € 7.4 billion for Covid-19 product and vaccine development needs...

Ellen 't Hoen - May 5, 2020

Recent Posts

The European Commission’s proposal for an EU wide compulsory licensing mechanism
Updated TRIPS Flexibilities Database
New WHO-UNITAID briefing paper: Improving Access to Covid-19 Treatments
Protecting Public Health through Technology Transfer: The Unfulfilled Promise of the TRIPS Agreement

Posts by Subject

Abbvie Access to Medicines Access to Vaccines ARIPO AstraZeneca C-TAP Cancer CDCA competition law Compulsory licensing compulsory licensing for export covid-19 Covid-19 Pool Covid-19 vaccine cystic fibrosis Data exclusivity Delinkage DNDi essential medicines list European Commission European Union evergreening Fair Pricing Gilead Hepatitis C human rights IFPMA LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands Orphan Drugs pandemic treaty Patents R&D remdesivir Sofosbuvir The Netherlands transparency TRIPS flexibilities TRIPS Waiver vaccines WHO WTO

Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: office@medicineslawandpolicy.net.

Home
Covid-19
Tools
TRIPS Flexibilities Database
Resources
Blog
About

This work is licensed under Creative Commons.